Neurological Manifestations of COVID-19
Main Article Content
Abstract
Objective of the article is to present more extensive data of manifestations of neurological disorders in patients with Covid 19.
Method. We gathered data from Pubmed, based on the words such as Covid 19, neurological disorder, neurological manifestation, complication, acute and long-term consequences, neurorehabilitation.
Results. The growing interest in the topic of Covid-19 is due to its systemic inflammation, multiple symptoms, course and consequences and increased risk of neurological disorders. Effects of coronavirus on the central nerve system are of concern. Covid 19 RNA was detected in spinal fluid that is a testament of the theory of its neurotrophic involvement.
Conclusion. Neurological clinical symptoms of Covid-19 are summarized as possible mechanism of coronavirus involvement in the brain.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Li Y, Wang M, Zhou Y, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. 2020.
https://media.tghn.org/medialibrary/2020/06/Li_2020_Preprint_Acute_cerebrovascular_disease_COVID19.pdf (preprint).
II. Covid-19 - Navigating the Uncharted. Fauci AS, Lane HC, Redfield RR N Engl J Med. 2020 Mar 26; 382(13):1268-1269.
III. Kieseier BC, Lehmann HC, Meyer Zu Hörste G. Autoimmune diseases of the peripheral nervous system/Autoimmun Rev. 2012 Jan; 11(3):191-5.
IV. Rubinos C, Ruland S. Neurologic Complications in the Intensive Care Unit/Curr Neurol Neurosci Rep. 2016 Jun; 16(6):57.
V. Mao L. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020
VI. Cui J., Li F ., Shi Z-L Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17: 181-192
VII. Baig A.M. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem. Neurosci. 2020; 11(7):995–998.
VIII. Li Y.C., Bai W.Z., Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. 2020
IX. Zhao J, Rudd A, Liu R. Challenges and potential solutions of stroke care during the coronavirus disease 2019 (COVID-19) outbreak. Stroke. Epub ahead of print 31 March 2020. DOI: 10.1161/STROKEAHA.120.029701.
X. Solomon T, Michael BD, Smith PE. Management of suspected viral encephalitis in adults—Association of British Neurologists and British Infection Association National Guidelines. J Infect. 2012; 64:347–373
XI. Slooter AJ, Otte WM, Devlin JW. Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies. Intensive Care Med. 2020; 46:1020–1022.
XII. Mao L, Jin H, Wang M. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020
XIII. Helms J, Kremer S, Merdji H. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020; 382:2268–2270.
XIV. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology. 2020https://doi.org.10.1148/radiol.2020201187 published online March 31.
XV. Paniz-Mondolfi A, Bryce C, Grimes Z. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) J Med Virol. 2020; 92:699–702.
XVI. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016; 388:717–727
XVII. Xu X.W. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606
XVIII. Luers JC, Klussmann JP, Guntinas-Lichius O. The Covid-19 pandemic and otolaryngology: what it comes down to? Laryngorhinootologie. 2020; 99:287–291.
XIX. Bénézit F, Le Turnier P, Declerck C. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30297-8. published online April 15
XX. Lechien JR, Chiesa-Estomba CM, De Siati DR. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020https://doi.org.10.1007/s00405-020-05965-1 published online April 6.
XXI. Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study. Eur J Neurol. 2020 https://doi.org.10.1111/ene.14273 published online April 22.
XXII. Moein ST, Hashemian SMR, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum AllergyRhinol. 2020 https://doi.org.10.1002/alr.22587 published online April 17
XXIII. Hornuss D, Lange B, Schröter N, Rieg S, Kern WV, Wagner D. Anosmia in COVID-19 patients. Clin Microbiol Infect. 2020https://doi.org.10.1016/j.cmi.2020.05.017 published online May 25.
XXIV. Jin H, Hong C, Chen S, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc Neurol 2020: svn-2020-000382. DOI: 10.1136/svn-2020-000382.
XXV. NHS England and NHS Improvement. Clinical guide for the management of stroke patients during the coronavirus pandemic.